Cardiac PET/CT and Prognosis

Patrycja Galazka, MD1 and Marcelo F. Di Carli, MD1

1Cardiovascular Imaging Program, Departments of Radiology and Medicine, the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, and the Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Received: 18 November 2016; Revised: 18 December 2016; Accepted: 22 December 2016

Abstract
Positron emission tomography (PET) is a powerful noninvasive imaging tool for phenotyping patients at risk of or with known coronary artery disease (CAD). One of the key advantages over other imaging modalities is its unique ability to quantify physiologic processes, including myocardial blood flow (in milliliters per minute per gram of myocardium), metabolism, and cardiac receptors, and its high sensitivity for delineating and quantifying molecular targets in vivo using targeted imaging probes. Cardiac PET/CT offers opportunity for a comprehensive noninvasive evaluation of the consequences of atherosclerosis in the coronary arteries and the myocardium.

Keywords: diagnosis and prognosis PET/CT; myocardial Scar/Ischemia; coronary flow reserve

Introduction
Positron emission tomography (PET) is a powerful noninvasive imaging tool for phenotyping patients at risk of or with known coronary artery disease (CAD) that has been evolving in the past 30 years. One of the key advantages over other imaging modalities is its unique ability to quantify physiologic processes, including myocardial blood flow (in milliliters per minute per gram of myocardium), metabolism, and cardiac receptors, and its high sensitivity for delineating and quantifying molecular targets in vivo using targeted imaging probes. The discussion that follows will review the emerging applications of cardiac PET/computed tomography (CT) in diagnosis and management of CAD.

Technical Considerations
Several technical advantages account for the improved image quality and diagnostic ability of PET compared with conventional radionuclide imaging, including (1) routine measured (depth-independent) attenuation correction (with either 68Ge sources for PET-only systems or CT for hybrid PET/CT scanners), which decreases the occurrence of false positives and thus increases specificity, (2) high spatial and contrast resolution (heart-to-background ratio) that allows improved detection of small perfusion defects, thereby decreasing the occurrence of false negatives and increasing sensitivity, and (3) high temporal resolution that allows fast dynamic imaging of tracer kinetics, which makes absolute quantification of myocardial perfusion (in milliliters per minute per gram of tissue) possible. In addition, the use of short-lived radiopharmaceuticals allows fast, sequential assessment of regional myocardial perfusion (e.g., rest and stress), thereby increasing laboratory efficiency and patient throughput.
Multiparametric PET/CT

All modern PET systems are now combined with a CT scanner into a hybrid PET/CT camera. Each component of the integrated system provides unique information for the evaluation of patients with known or suspected CAD as described later. Figure 1 illustrates current state-of-the-art cardiac PET/CT protocols for the evaluation of known or suspected CAD. As discussed later, each of the components of the multiparametric imaging protocol provide complementary information regarding diagnosis and risk stratification.

Emission Scans

Because of the short physical half-life of PET radiopharmaceuticals for the assessment of myocardial perfusion, approximately the same dose is injected for both rest and stress myocardial perfusion studies. The injected doses are adjusted according to the size of the patient and the type of PET data acquisition (i.e., 2-D mode vs. 3-D mode). List mode imaging has become standard practice with modern PET technology, which allows a comprehensive multiparametric examination (Figure 1), which includes the assessment of myocardial perfusion, left ventricular ejection fraction (LVEF) and left ventricular (LV) volumes, and quantitative coronary blood flow and flow reserve in the same setting. In select patients with severe LV dysfunction, metabolic imaging with fluorodeoxyglucose (FDG) is used to assess myocardial viability.

CT Scans

Low-dose CT scans are used for positioning patients in the scanner field of view. A low-dose nongated CT scan covering the heart region (transmission scan) is then used for correction of the inhomogeneities of radiotracer distribution in the PET images caused by overlapping soft tissue (e.g., breast, diaphragm). This postprocessing step is known as attenuation correction and is mandatory for cardiac PET. In select patients, a gated CT scan may be obtained to calculate a coronary artery calcium (CAC) score.
PET/CT Imaging Markers Used in Diagnostic and Prognostic Evaluation of CAD

Quantification of Myocardial Ischemia and Scar

Regional myocardial perfusion is usually assessed by semiquantitative visual analysis of the rest and stress images. The segmental scores are then summed to give global scores (the summed stress score reflects the extent and severity of ischemia plus scar; the summed rest score reflects the extent and transmurality of scar; the summed difference score reflects the extent and severity of ischemia) that reflect the total burden of ischemia and scar in the left ventricle. These global scores are typically expressed as a percentage of the LV mass, which is estimated by division of the corresponding global score by the total maximum score possible [17 segments×4 (worst score in a given segment)=68]. The semiquantitative (visual) and quantitative scores of ischemia and scar reflect the extent and severity of CAD, and are linearly related to the risk of adverse cardiovascular events. Large and severe perfusion defects (typically involving more than 10% of the LV mass), and those involving multiple coronary territories are associated with higher clinical risk. Therefore the quantification of ischemia and scar is useful in guiding patient treatment, especially the need for revascularization. The presence of transient LV dilatation during stress imaging (so-called transient ischemic dilatation) is an ancillary marker of risk that reflects extensive subendocardial ischemia from multivessel obstructive coronary stenosis and/or microvascular dysfunction (Figure 2).

Quantification of Myocardial Blood Flow and Coronary Flow Reserve

Myocardial blood flow (in milliliters per minute per gram of myocardium) and coronary flow reserve (CFR; defined as the ratio between peak stress and rest myocardial blood flow) are important physiologic parameters that can be measured by routine postprocessing of myocardial perfusion PET images (Figure 3). These absolute measurements of tissue perfusion are accurate and reproducible. CFR estimates provide a measure of the integrated effects of epicardial coronary stenoses, diffuse atherosclerosis and vessel remodeling, and microvascular dysfunction on myocardial perfusion, and, as such, the value obtained is a more sensitive measure of myocardial ischemia. In the setting of increased oxygen demand such as during exercise, a reduced CFR can upset the supply-demand relationship and lead to myocardial ischemia, subclinical LV dysfunction (diastolic and systolic), symptoms, and death. As discussed later, these measurements of CFR have important diagnostic and prognostic implications in the evaluation and treatment of patients with known or suspected CAD.

Assessment of Myocardial Viability

Myocardial perfusion imaging (MPI) and metabolic imaging are commonly used to evaluate the patient with ischemic LV dysfunction, especially when the question of revascularization is being considered. Radionuclide imaging provides important quantitative information, including (1) myocardial infarct size, (2) extent of stunning and hibernating myocardium, (3) magnitude of inducible myocardial ischemia, and (4) LV function and volumes. Metabolic imaging with PET has been extensively validated and is commonly used for assessment of myocardial viability. \(^{18}\)FDG is used to assess regional myocardial glucose utilization (an index of tissue viability) and the images obtained are compared with perfusion images to define metabolic abnormalities associated with infarction and hibernation. Reduced perfusion and increased FDG uptake at rest (so-called perfusion-FDG mismatch) identifies areas of viable but hibernating myocardium, whereas regions showing both reduced perfusion and reduced FDG uptake at rest (so-called perfusion-FDG match) are consistent with myocardial scar (Figure 4). As discussed later, these metabolic patterns are powerful markers of risk, and have important implications for the selection of patients for revascularization.
Coronary blood flow Microcirculatory dysfunction

EPICARDIAL ARTERIES (> 400 μm)
SMALL ARTERIES (< 400 μm)

FFR
Pressure difference

CFR = \frac{MBF_{\text{rest}}}{MBF_{\text{stress}}}

Figure 3  Conceptual Schematic of Coronary Flow Reserve (CFR) Measurements. CFR is a quantitative measure of coronary vascular dysfunction that integrates the hemodynamic effects of focal, diffuse, and small-vessel coronary artery disease on myocardial tissue perfusion. CFR is calculated as the ratio of hyperemic to rest absolute myocardial blood flow (MBF). In contrast, measurements of fractional flow reserve (FFR) integrate only the effects of focal epicardial stenosis and diffuse atherosclerosis.

Quantification of LV Function and Volumes
The acquisition of ECG-gated myocardial perfusion images allows quantification of regional and global systolic function, and LV volumes. With PET, ECG-gated images are typically collected at rest and during stress. Rest LVEF measurements are helpful to define the patient’s risk after myocardial infarction. A drop in LVEF during pharmacologic stress can be helpful to identify high-risk patients.

Quantification of Coronary Artery Calcifications
The widespread use of integrated PET/CT scanners allows the routine quantification of CAC scores,
Cardiac PET/CT in Diagnosis, Risk Stratification, and Management of CAD

Diagnosis of CAD

Recent meta-analyses [2, 3] and a prospective European multicenter study [4] have confirmed the high sensitivity and diagnostic accuracy of PET MPI for the detection of significant angiographic stenosis. In addition, a more recent meta-analysis using fractional flow reserve (FFR) as a gold standard for flow-limiting CAD demonstrated high sensitivity, specificity, negative predictive value, and positive predictive value for PET [5] (Figure 5). In this analysis, PET’s performance in excluding abnormal FFR was comparable to that of cardiac MRI and CT, and superior to that of both single photon emission (SPECT) and echocardiography. As described earlier, one additional advantage of PET is that it allows routine quantification of myocardial blood flow and CFR. These quantitative measures of myocardial perfusion increase the sensitivity and the negative predictive value of PET for ruling out high-risk angiographic CAD [6–10].

Risk Stratification of Known or Suspected CAD with PET MPI

The power of radionuclide MPI (including PET) for risk stratification is based on the fact that the major determinants of prognosis in patients with
CAD are readily available from gated MPI. These include the amount of myocardial scar, the extent and severity of stress-induced ischemia, and measurements of LV size (i.e., volumes) and LVEF. Optimal risk stratification is based on the concept that the risk associated with a normal study is sufficiently low that revascularization will not further improve patient outcomes. Hence catheterization is an unlikely option after testing. Conversely, patients with abnormal stress imaging results are at greater risk of adverse events and thus are potential candidates for intervention, and the magnitude of their risk is related to the extent and severity of the imaging abnormalities.

There is growing and consistent evidence documenting the value of PET MPI in risk stratification of CAD. In general, normal PET MPI findings are associated with a very low risk of adverse cardiac events, and the risk increases linearly with the extent and severity of perfusion abnormalities. Multiple single-center studies and a large multicenter registry have demonstrated that the concept of progressive risk stratification initially shown with SPECT MPI abnormalities is also applicable to PET studies. In a large multicenter observational registry of 7061 patients with known or suspected CAD from four sites (median follow-up 2.2 years), stress PET results added incremental value over preimaging data for the prediction of cardiac death. Risk-adjusted analyses revealed that mildly, moderately, and severely abnormal findings were associated with a stepwise increase in clinical risk (Figure 6). The study showed that for each 10% increase in ischemic and scarred myocardium, the risk of cardiac death increased by 34% and 57% respectively. Patients with severely abnormal stress PET MPI findings had a nearly five-fold higher risk of cardiac death compared with patients with normal PET MPI findings, even after other clinical risk markers had been accounting for. Further, PET MPI results enhanced net reclassification improvement [11].

A recent study from this registry addressed the question of sex-related prognostic differences after stress PET and demonstrated that PET MPI yielded incremental prognostic value in both sexes, which, in turn, was associated with similar magnitudes of risk in men and women. Finally, a complementary study from this registry showed that normal PET MPI findings were associated with an excellent prognosis with very low annual cardiac death rates in normal (0.38%), overweight (0.43%), and obese (0.15%) patients. As shown for other cohorts, risk increased with increasing degree of perfusion abnormalities in PET MPI [12].

**Ancillary Markers of Clinical Risk**

As for conventional radionuclide perfusion imaging, the use of ECG gating is an integral part of the PET MPI examination, thereby allowing quantification of regional and global LV systolic function and volumes, and improved risk stratification. Indeed, the presence of normal LVEF and wall motion abnormalities is also associated with a lower-risk cohort even in the setting of perfusion abnormalities [13]. Conversely, the presence of LV dilatation (transient or fixed), wall motion abnormalities either at rest or after stress, and reduced LVEF have all been well described as markers of increased patient risk.

A unique aspect of PET MPI resides in its ability to quantify LVEF at rest and during peak stress, similarly to stress echocardiography. In normal individuals, LVEF increases during peak vasodilator stress [14]. In patients with obstructive CAD, however, the change in LVEF from the baseline to peak

![Figure 6](https://example.com/figure6.png)

**Figure 6** Positron Emission Tomography Myocardial Perfusion Imaging for Risk Stratification. Adjusted Kaplan-Meier survival curves and hazard ratios by extent of myocardium with abnormal perfusion. CD, cardiac deaths; CI, confidence interval; HR, hazard ratio; Reproduced with permission from Dorbala et al. [11].
stress (so-called LVEF reserve) is inversely related to the extent of obstructive angiographic CAD [14]. Patients with obstructive multivessel or left main artery disease show a frank drop in LVEF during peak stress even in the absence of apparent perfusion defects. In contrast, those without significant CAD or with mild angiographic CAD show a normal increase in LVEF [14–16]. More importantly, the lack of augmentation in LVEF from the baseline to peak stress identifies patients at increased risk of adverse cardiac events and provides incremental risk stratification [14].

The presence of transient LV dilatation and increased right ventricular tracer uptake with stress are also markers of diffuse myocardial ischemia from obstructive multivessel CAD and/or microvascular dysfunction and are associated with increased risk (Figure 2).

**Coronary Flow Reserve**

In addition to the diagnostic utility of quantitative measures of myocardial blood flow discussed already, CFR is also emerging as a powerful quantitative prognostic imaging marker of clinical cardiovascular risk. From a pathophysiologic viewpoint, CFR provides a robust and reproducible clinical measure of the integrated hemodynamic effects of epicardial CAD, diffuse atherosclerosis, vessel remodeling, and microvascular dysfunction on myocardial tissue perfusion. Consequently, it is a more sensitive measure of myocardial ischemia and overall vascular health that provides unique information about clinical risk. The available data thus far suggest that CFR measurements by PET can distinguish patients at high risk of serious adverse events, including cardiac death [10, 17–19]. A severely reduced CFR (<1.5) was associated with a nearly sixfold increased risk of cardiac death compared with a relatively preserved CFR (>2.0) (Figure 7), even after adjustment for differences in clinical risk, the extent and severity of ischemia and scar, and LVEF, and led to clinically meaningful risk reclassification of approximately 50% of intermediate-risk patients [17]. Importantly, an abnormal CFR identified increased risk of cardiac death even among those patients with normal scans by semiquantitative visual analysis. As discussed, the noninvasive PET measure of CFR has been able to improve risk classification, especially among high-risk cohorts (e.g., diabetic patients, non-ST-elevation myocardial infarction patients, in patients with chronic renal impairment, and in those with high CAC scores) [20–22]. For example, a reduced global CFR was independently associated with higher rates of cardiac and all-cause death in a large cohort of patients with and without diabetes mellitus. Compared with diabetic patients with preserved CFR, those with reduced CFR experienced substantially higher cardiac mortality [20] (Figures 8 and 9). Importantly, diabetic patients without known CAD and with impaired CFR experienced a rate of cardiac death comparable to, and possibly higher than, that for nondiabetic patients with known CAD. These observations have implications for the classification of diabetes mellitus as a coronary disease risk equivalent [23]. Specifically, only among diabetic patients with impaired vascular function is the prognosis comparable to that for nondiabetic patients with known CAD. Thus differing levels of vascular health among previously studied cohorts may account for inconsistencies in the relative mortality rates of diabetic patients without CAD and nondiabetic patients with CAD [24–26]. Thus the ability to assess CFR appears to permit a level of risk assessment beyond that achieved previously, with the potential to incorporate vascular/endothelial status into routine patient investigations. In patients with impaired

![Figure 7](image_url)
Figure 8  Examples of Risk Reclassification by Coronary Flow Reserve (CFR).  
Top panel: A 58-year-old man with hypertension and diabetes evaluated for atypical chest pain with positron emission tomography (PET) myocardial perfusion imaging (MPI). The study shows normal myocardial perfusion and CFR>2 in all coronary territories. Lower panel: A 63-year-old man with hypertension, diabetes, and high cholesterol level evaluated for dyspnea. PET MPI shows normal myocardial perfusion but CFR is severely reduced in all coronary territories, consistent with severe microvascular dysfunction. LAD, left anterior descending artery; LCX, left circumflex artery; LV, left ventricle; RCA, right coronary artery.

Figure 9  Coronary Flow Reserve (CFR) Reclassifies Risk of Cardiac Death in Diabetic Patients.  
Adjusted annualized cardiac mortality rates among patients stratified by the presence or absence of diabetes mellitus (DM) and coronary artery disease (CAD). EF, ejection fraction; LVEF, left ventricular ejection fraction; MPI, myocardial perfusion imaging; NI, no ischemia. Reproduced with permission from Murthy et al. [20].

CFR and severely obstructive CAD, preliminary data support a possible benefit from revascularization by coronary artery bypass grafting (Figure 10) [21]. This ability to quantify CFR extends the potential for evaluation of risk to those patients in the past not considered to be candidates for testing. Even in patients without CAD and with normal LV function,
after adjustment for multiple confounders, impaired CFR was associated with both the occurrence of a positive troponin test and with major downstream adverse events [21]. With use of PET-derived CFR, the prognostic impact of coronary microvascular dysfunction was assessed in 405 men and 813 women who were identified as having no prior CAD as well as no perfusion abnormalities in their PET MPI studies [27]. Coronary microvascular dysfunction, defined as a CFR of less than 2.0 in these patients, was a frequent finding in both men and women (51% and 54% respectively). Patients were followed up for a median of 1.3 years for the composite end point of cardiac death, nonfatal myocardial infarction, late revascularization, and hospitalization for heart failure. In both men and women, CFR added incremental prognostic value (hazard ratio 0.80 [95% confidence interval 0.75–0.86] per 10% increase in CFR) and appropriately reclassified patients with respect to risk, as assessed by significant net reclassification improvement (Figure 11). These findings suggest that coronary microvascular dysfunction is a widespread finding and that work is needed to identify its putative role as a therapeutic target.

**CAC and Coronary Artery Plaque Characterization**

As all modern PET scanners are combined with CT scanners, we are beginning to understand the potential complementary roles between structure and function for diagnosis and management of CAD. There is growing evidence that CAC scores are generally predictive of a higher likelihood of ischemia (reflecting obstructive CAD) on MPI [28–31]. However, the relationship between the extent and the severity of coronary calcification and measures of myocardial ischemia reflecting obstructive CAD is quite modest [32, 33]. Importantly, CAC scores less than 400, especially in symptomatic patients with intermediate likelihood of CAD, have limited sensitivity and negative predictive value to exclude CAD especially in young individuals and women [31, 34, 35].

The integration of CAC scores and ischemia information also offers a unique opportunity to refine the prognostic value of myocardial perfusion PET. The CAC score, reflecting the anatomic extent of atherosclerosis [36], offers an opportunity to improve the conventional models for risk assessment using nuclear imaging alone (especially in patients with normal perfusion). For example, the presence of extensive coronary artery calcifications in a patient with normal PET MPI findings identifies patients at higher risk of adverse cardiac events as compared with patients with normal MPI findings and no or mild coronary artery calcifications [31] (Figure 12).

With the addition of intravenous contrast material, coronary CT angiography further expands the role of hybrid PET/CT for diagnosis and management...
of CAD. There is evidence that hybrid imaging may offer superior diagnostic information with regard to identification of the culprit vessel [37–40]. Coronary CT angiography enhances the sensitivity for detection of multivessel CAD, while MPI increases the specificity and positive predictive value for delineation of flow-limiting coronary artery stenosis. The addition of coronary CT angiography is also quite helpful to help exclude severe coronary artery obstruction among patients with severely reduced CFR [8].

**Myocardial Metabolism for Delineation of Myocardial Viability**

PET has an established role in the evaluation of myocardial ischemia and viability in patients with ischemic heart failure. Several studies using different radionuclide approaches including PET have shown that the gain in global LVEF after revascularization is related to the magnitude of viable myocardium assessed preoperatively. These data demonstrate that clinically meaningful changes in global LV function can be expected after revascularization only in patients with relatively large areas of hibernating and/or stunned myocardium (~20% of the LV mass). In addition to the obtaining of information regarding viability, ischemia assessment can also be performed during the same examination. The use of viability imaging also plays a role in determining the size and extent of scar in planning optimal implantable cardiac defibrillator/cardiac resynchronization therapy lead position in patients with ischemic cardiomyopathy. Studies have shown that CRT-D (implantable cardiac defibrillators enabled with cardiac resynchronization therapy) devices are more successful when the lead position is in an area of viable myocardium, with improved LV systolic function and outcomes [41].
More importantly, there are consistent data from single-center, observational studies demonstrating that the presence of ischemic, viable myocardium among patients with severe LV dysfunction identifies patients at higher clinical risk, and that prompt revascularization in select patients is associated with improved LV function, abatement of symptoms, and increased survival as compared with medical therapy alone [42]. The randomized PARR-2 clinical trial demonstrated that PET-guided decisions regarding revascularization could also help improve clinical outcomes following revascularization if treatment decisions adhere to imaging recommendations [43].

**Conclusions**

PET/CT is a powerful tool for translational research that offers unique quantitative insights into molecular processes in vivo. Hybrid PET/CT is rapidly advancing our ability to image in great detail the structure and function of the heart and vasculature. By providing concurrent quantitative information about myocardial blood flow and metabolism with coronary and cardiac anatomy, PET/CT offers the opportunity for a comprehensive noninvasive evaluation of the consequences of atherosclerosis in the coronary arteries and the myocardium. This integrated platform for assessing anatomy and biology expands the potential for translating molecularly targeted imaging into humans.

**Conflict of Interest**

The authors declare no conflict of interest.
REFERENCES

1. Di Carli, Hachamovitch R. New technology for noninvasive evaluation of coronary artery disease. Circulation 2007; 20;115(11):1464–80.
2. Mc Ardle BA, Dowsley TF, deKemp RA, Wells GA, Beanlands RS. Does rubidium-82 PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease?: A systematic review and meta-analysis. J Am Coll Cardiol 2012;60(18):1828–37.
3. Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis. Circ Cardiovasc Imaging 2012;5(6):700–7.
4. Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguade-Bruix S, et al. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging 2015;8(3):e002179.
5. Takx RA, Blomberg BA, El Aidi H, Habets J, de Jong PA, Nagel E, et al. Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis. Circ Cardiovasc Imaging 2015;8(1):e002660.
6. Danad I, Uusitalo V, Kero T, Saraste A, Rajmakers PG, Lammertma AA, et al. Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease: cutoff values and diagnostic accuracy of quantitative [15O]H2O PET imaging. J Am Coll Cardiol 2014;64(14):1464–75.
7. Johnson NP, Gould KL. Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve. JACC Cardiovasc Imaging 2011;4(9):990–8.
8. Kajander S, Joutsiniemi E, Saraste M, Pietila M, Ukkonen H, Saraste A, et al. Cardiac positron emission tomography/computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease. Circulation 2010;122(6):603–13.
9. Naya M, Murthy VL, Taqueti VR, Foster CR, Klein J, Garber M, et al. Preserved coronary flow reserve effectively excludes high-risk coronary artery disease on angiography. J Nucl Med 2014;55(2):248–55.
10. Ziadi MC, Dekemp RA, Williams K, Guo A, Renaud JM, Chow BJ, et al. Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease? J Nucl Cardiol 2012;19(4):670–80.
11. Dobrula S, Di Carli MF, Beanlands RS, Merhige ME, Williams BA, Veledar E, et al. Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J Am Coll Cardiol 2013;61(2):176–84.
12. Chow BJ, Dobrula S, Di Carli MF, Merhige ME, Williams BA, Veledar E, et al. Prognostic value of PET myocardial perfusion imaging in obese patients. JACC Cardiovasc Imaging 2014;7(3):278–87.
13. Dobrula S, Hachamovitch R, Curillova Z, Thomas D, Vangala D, Kwong RY, et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. JACC Cardiovasc Imaging 2009;2(7):846–54.
14. Dobrula S, Vangala D, Sampson U, Limaye A, Kwong R, Di Carli MF. Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: a 82Rb PET/CT study. J Nucl Med 2007;48(3):349–58.
15. Brown TL, Merrill J, Volokh L, Bengel FM. Determinants of the response of left ventricular ejection fraction to vasodilator stress in electrocardiographically gated 82rubidium myocardial perfusion PET. Eur J Nucl Med Mol Imaging 2008;35(2):336–42.
16. Van Tosh A, Votaw JR, Reichek N, Palestro CJ, Nichols KJ. The relationship between ischemia-induced left ventricular dysfunction, coronary flow reserve, and coronary steal on regadenoson stress-gated 82Rb PET myocardial perfusion imaging. J Nucl Cardiol 2013;20(6):1060–8.
17. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011;124(20):2215–24.
18. Fukushima K, Javadi MS, Higuchi T, Lautamaki R, Merrill J, Nekolla SG, et al. Prediction of short-term cardiovascular events using quantification of global myocardial flow reserve in patients referred for clinical 82Rb PET perfusion imaging. J Nucl Med 2011;52(5):726–32.
19. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009;54(2):150–6.
20. Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012;126(15):1858–68.
21. Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 2015;131(1):19–27.
22. Naya M, Murthy VL, Foster CR, Gaber M, Klein J, Hainer J, et al. Prognostic interplay of coronary artery calcification and
underlying vascular dysfunction in patients with suspected coronary artery disease. J Am Coll Cardiol 2013;61(20):2098–106.

23. Roger VL, Weston SA, Killian JM, Pfeifer EA, Belau PG, Kottek TE, et al. Time trends in the prevalence of atherosclerosis: a population-based autopsy study. Am J Med 2001;110(4):267–73.

24. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabetic Med 2009;26(2):142–8.

25. Schramm TK, Gislason GH, Kobert L, Rasmussen S, Rasmussen JN, Abildstrom SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008;117(15):1945–54.

26. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011;171(5):404–10.

27. Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 2014;129(24):2518–27.

28. He ZX, Hedrick TD, Pratt CM, Verani MS, Aquino V, Roberts R, et al. Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia. Circulation 2000;101(3):244–51.

29. Berman DS, Wong ND, Gransar H, Miranda-Peats R, Dahlbeck J, Hayes SW, et al. Relationship between stress-induced myocardial ischemia and atherosclerosis measured by coronary calcium tomography. J Am Coll Cardiol 2004;44(4):923–30.

30. Schepis T, Gaemperli O, Koeppfl i P, Namdar M, Valenta I, Scheffel H, et al. Added value of coronary artery calcium score as an adjunct to gated SPECT for the evaluation of coronary artery disease in an intermediate-risk population. J Nucl Med 2007;48(9):1424–30.

31. Schenker MP, Dorbala S, Hong EC, Rybicki FJ, Hachamovitch R, Kwong RY, et al. Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: a combined positron emission tomography/computed tomography study. Circulation 2008;117(13):1693–700.

32. Curillova Z, Yaman BF, Dorbala S, Kwong RY, Sitek A, El Fakhri G, et al. Quantitative relationship between coronary calcium content and coronary flow reserve as assessed by integrated PET/CT imaging. Eur J Nucl Med Mol Imaging 2009;36(10):1603–10.

33. Naya M, Murthy VL, Blankstein R, Sitek A, Hainer J, Foster C, et al. Quantitative relationship between the extent and morphology of coronary atherosclerotic plaque and downstream myocardial perfusion. J Am Coll Cardiol 2011;58(17):1807–16.

34. Knezevic A, Becker A, Leber A, White C, Becker CR, Reiser MF, et al. Relation of coronary calcium scores by electron beam tomography to obstructive disease in 2,115 symptomatic patients. Am J Cardiol 2004;93(9):1150–2.

35. Vavere AL, Simon GG, George RT, Rochitte CE, Arai AE, Miller JM, et al. Diagnostic performance of combined noninvasive coronary angiography and myocardial perfusion imaging using 320 row detector computed tomography: design and implementation of the CORE320 multicenter, multinational diagnostic study. J Cardiovasc Comput Tomogr 2011;5(6):370–81.

36. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Greigore J, Fitzpatrick LA, et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalifying methodology. J Am Coll Cardiol 1998;31(1):126–33.

37. Gaemperli O, Schepis T, Koeppfl i P, Valenta I, Soyka J, Leshka S, et al. Accuracy of 64-slice CT angiography for the detection of functionally relevant coronary stenoses as assessed with myocardial perfusion SPECT. Eur J Nucl Med Mol Imaging 2007;34(8):1162–71.

38. Namdar M, Hany TF, Koeppfl i P, Siegrist PT, Burger C, Wyss CA, et al. Integrated PET/CT for the assessment of coronary artery disease: a feasibility study. J Nucl Med 2005;46(6):930–5.

39. Rispler S, Keidzar Z, Gershin E, Roguin A, Soil A, Dragu R, et al. Integrated single-photon emission computed tomography and computed tomography coronary angiography for the assessment of hemodynamically significant coronary artery lesions. J Am Coll Cardiol 2007;49(10):1059–67.

40. Di Carli MF, Dorbala S, Curillova Z, Kwong RJ, Goldhaber SZ, Rybicki FJ, et al. Relationship between CT coronary angiography and stress perfusion imaging in patients with suspected ischemic heart disease assessed by integrated PET-CT imaging. J Nucl Cardiol 2007;14(6):799–809.

41. Bax JJ, Delgado V. Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol 2015;22(2):229–45.

42. Mielniczuk LM, Beanlands RS. Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Imaging-guided selection of patients with ischemic heart failure for high-risk revascularization improves identification of those with the highest clinical benefit. Circ Cardiovasc Imaging 2012;5(2):262–70; discussion 270.

43. Beanlands RS, Nichol G, Huszt E, Humen D, Racine N, Freeman M, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50(20):2002–12.